-
公开(公告)号：US20200247839A1
公开(公告)日：2020-08-06
申请号：US16784296
申请日：2020-02-07
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Guoqiang Wang , Yong He , Peng Dai , Guoyou Xu , Bin Wang , Jiang Long , Yat Sun Or
Abstract: The present invention relates to processes for preparing a compound of Formula I: or a pharmaceutically acceptable salt or solvate thereof, and intermediates of use in said processes.
-
公开(公告)号：US10472386B2
公开(公告)日：2019-11-12
申请号：US15896400
申请日：2018-02-14
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Guoqiang Wang , Yat Sun Or , Ruichao Shen , Xuechao Xing , Jiang Long , Peng Dai , Brett Granger , Jing He
Abstract: The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, prodrugs and esters thereof, The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.
-
公开(公告)号：US10457703B2
公开(公告)日：2019-10-29
申请号：US15085800
申请日：2016-03-30
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Guoqiang Wang , Yat Sun Or , Ruichao Shen , Xuechao Xing , Jiang Long , Peng Dai , Brett Granger , Jing He
Abstract: The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, stereoisomers, solvates, hydrates or combination thereof, The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.
-
公开(公告)号：US10364267B2
公开(公告)日：2019-07-30
申请号：US15439358
申请日：2017-02-22
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Guoqiang Wang , Yat Sun Or , Jiang Long , Guoyou Xu , Peng Dai , Ruichao Shen , Xuechao Xing , Jing He
Abstract: The present invention provides compounds of Formula (I) or Formula (II): pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR and/or TGR5.
-
公开(公告)号：US11958879B2
公开(公告)日：2024-04-16
申请号：US17324464
申请日：2021-05-19
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Guoqiang Wang , Yat Sun Or , Ruichao Shen , Xuechao Xing , Jiang Long , Peng Dai , Brett Granger , Jing He
CPC classification number: C07J43/003 , C07J41/005 , C07J41/0055 , C07J41/0088 , C07J9/00 , C07J9/005 , C07J51/00
Abstract: The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, stereoisomers, solvates, hydrates or combination thereof,
The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.-
Patent Agency Ranking
公开(公告)号：US11718641B2
公开(公告)日：2023-08-08
申请号：US17186447
申请日：2021-02-26
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Guoqiang Wang , Yat Sun Or , Ruichao Shen , Jiang Long , Peng Dai , Xuechao Xing , Jing He
CPC classification number: C07J41/0066 , C07J41/0055 , C07J41/0088 , C07J43/003 , C07J43/006 , C07J9/005 , C07J41/0094 , C07J51/00
Abstract: The present invention provides compounds of Formula I,
pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.-
公开(公告)号：US20220402966A1
公开(公告)日：2022-12-22
申请号：US17324464
申请日：2021-05-19
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Guoqiang Wang , Yat Sun Or , Ruichao Shen , Xuechao Xing , Jiang Long , Peng Dai , Brett Granger , Jing He
Abstract: The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, stereoisomers, solvates, hydrates or combination thereof, The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.
-
公开(公告)号：US11040998B2
公开(公告)日：2021-06-22
申请号：US16593262
申请日：2019-10-04
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Guoqiang Wang , Yat Sun Or , Ruichao Shen , Xuechao Xing , Jiang Long , Peng Dai , Brett Granger , Jing He
Abstract: The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, stereoisomers, solvates, hydrates or combination thereof, The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.
-
公开(公告)号：US10947264B2
公开(公告)日：2021-03-16
申请号：US16784296
申请日：2020-02-07
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Guoqiang Wang , Yong He , Peng Dai , Guoyou Xu , Bin Wang , Jiang Long , Yat Sun Or
Abstract: The present invention relates to compounds of Formulas 3-6, where R4 PG1 and PG2 are defined as disclosed herein. These compounds are useful as intermediates in processes for preparing a compound of Formula I: where R1 is defined as disclosed herein.
-
公开(公告)号：US10519191B2
公开(公告)日：2019-12-31
申请号：US14952526
申请日：2015-11-25
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Yat Sun Or , Ruichao Shen , Peng Dai , Jiang Long , Xuechao Xing , Guoqiang Wang
Abstract: The present invention relates to compounds of Formula (IA) and Formula (IB), and pharmaceutically acceptable salts thereof, where R1, R2, R3, R4, R5, R6, R7, R8, R9 and m are as defined herein, pharmaceutical compositions comprising these compounds and methods of use of these compounds for treating a TGR5 mediated disease or condition.
-
-
-
-
-
-
-
-
-
Search Results
24
records
(took 0.026 seconds)
